Home › Research › Treatments
[Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial]
Yu L, Lin SM, Zhou RQ, Tang WJ, Huang PX, Dong Y, Wang J, Yu ZH et al.. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine, 2012-07-01
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background Alzheimer disease (AD) is a chronic neurodegenerative disease that is characterized by its gradual progression. At present, the cause and mechanism of AD are yet unclear, and there is no effective therapy for treating it. With development of global aging, the prevalence rate of AD is increasing. The life quality of elderly people is affected severely by AD that is ultimately life-threatening. Recently, study on treating AD with traditional Chinese medicine (TCM) has deepened. Objective To explore the therapeutic effects of a syndrome differentiation-based TCM regime in treating patients with mild to moderate AD for improving cognition, and to evaluate the changes in brain function of AD patients observed by resting-state functional magnetic resonance imaging (fMRI) technique. Design, setting, participants and interventions Adopting the internationally recognized criteria developed by National Institute of Neurological and Communicative Diseases and Stroke/Alzheimer's Disease and Related Disorders Association, the clinical trial was conducted on 131 patients with mild to moderate AD from 5 communities and 7 social welfare institutions. Participants were accepted after informed consent was received, and laboratory tests and a head imaging study were conducted. The patients were randomly divided into Chinese medicine group (CMG) (66 cases) or Western medicine group (WMG) (65 cases). Patients in the CMG were treated monthly with Chinese medicine according to syndrome differentiation. Patients in the WMG were treated with donepezil at a dose of 5 mg once daily. The therapeutic course lasted 48 weeks. Main outcome measures The scores of Mini-Mental State Examination (MMSE), Fuld Object-Memory Evaluation (FOM), Block Design (BD) and Digit Span (DS) were used to evaluate the cognitive function; resting-state fMRI was used for observing brain function. The questionnaires and fMRI were performed before and after treatments. Results The cognitive functions of the patients in the CMG and WMG were improved after treatment. MMSE score was improved significantly in both groups (P Conclusion TCM treatment based on syndrome differentiation is effective in improving cognitive function of patients with mild to moderate AD and increasing the brain function by increasing connectivity between posterior cingulated gyrus and specific areas in the brain.
What this study adds
Evidence grade: Low
This is a trial of 131 participants. Cognitive function improved in both the Chinese medicine and Western medicine groups of patients with mild to moderate Alzheimer disease. The study does not report whether one treatment was better than the other, and it does not show a cure or prevention.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Yu, L., Lin, S. M., Zhou, R. Q., Tang, W. J., Huang, P. X., Dong, Y., et al. (2012). [Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. https://doi.org/10.3736/jcim20120707
Vancouver
Yu L, Lin SM, Zhou RQ, Tang WJ, Huang PX, Dong Y, et al. [Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial]. Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine. 2012. doi:10.3736/jcim20120707. PMID: 22805083.
BibTeX
@article{yu2012-22805083,
author = {Yu, L. and Lin, S. M. and Zhou, R. Q. and Tang, W. J. and Huang, P. X. and Dong, Y. and Wang, J. and Yu, Z. H. and others},
title = {{[Chinese herbal medicine for patients with mild to moderate Alzheimer disease based on syndrome differentiation: a randomized controlled trial]}},
journal = {Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine},
year = {2012},
doi = {10.3736/jcim20120707},
pmid = {22805083},
url = {https://doi.org/10.3736/jcim20120707}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.
Key findings
- Results The cognitive functions of the patients in the CMG and WMG were improved after treatment.
- MMSE score was improved significantly in both groups (P Conclusion TCM treatment based on syndrome differentiation is effective in improving cognitive function of patients with mild to moderate AD and increasing the brain function by increasing connectivity between posterior cingulated gyrus and spe
Why it matters
Cognitive function improved in both the Chinese medicine and Western medicine groups of patients with mild to moderate Alzheimer disease. The study does not report whether one treatment was better than the other, and it does not show a cure or prevention.
New to this subject? Start with our plain-English guide: Treatments →
Study details
- Participants131
- Evidence strengthLow
How this study scored 51/100
Published in a peer-reviewed journal, and it is a randomized controlled trial. Scored zero for effect reported because the record does not state it. We have no data on journal's citation record, senior author's track record and institution's track record, so those were left out: it earned 45 of the 89 points we could judge it on, which is 51 out of 100.
| Component | Points | Why |
|---|---|---|
| Journal tier | 7 / 10 | Tier 3 — peer-reviewed journal (Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine) |
| Journal's citation record | — / 4 | No journal record from OpenAlex — left out of this score |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2012 — within 20 year(s) of the newest study here |
| Sample size | 2 / 4 | 131 participants |
| Effect reported | 0 / 3 | No effect size reported — scores zero (not stated in the record — scored 0) |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 1 / 2 | Randomized (as stated in the record) |
| Times cited | 3 / 7 | Cited 24 times (OpenAlex, 2026-10-10) |
| Citations per year | 1 / 5 | 1.5 citations a year over 16 year(s) since 2012 |
| Impact for its field and year | 2 / 6 | Cited 1.2× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 0 / 6 | No other study in this library cites it |
| Still being cited | 1 / 4 | Cited 5 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | — / 4 | OpenAlex's profile for last-listed author Lu Yu holds only 1 work(s), too few to judge a track record — left out of this score |
| Institution's track record | — / 3 | No institution listed in OpenAlex — left out of this score |
| Multicenter collaboration | 0 / 3 | OpenAlex lists 0 institution(s) in 0 countries — scores zero (affiliation lists can be incomplete) |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 22805083) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Points | 45 / 89 | Scored on 17 of 20 parts. We have no data for the rest, so they are left out: 45 of the 89 points we could judge it on is 51 out of 100. |
| Total | 51 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription Unpaywall, Europe PMC and OpenAlex found no free copy of the full text (checked 10 Oct 2026), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Related studies in Treatments from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.